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NERVE TREATMENT METHODS tation member configured to extend about the first nerve 
segment and engage the first nerve segment . The apparatus 
CROSS - REFERENCE TO RELATED further includes a second coaptation member configured to 
APPLICATION connect to the first coaptation member and extend about the 
second nerve segment . The second coaptation member 
This application is a continuation of U . S . application Ser . includes a first coupling member and a second coupling 
No . 14 / 001 , 431 , filed Jan . 3 , 2014 , which is a national phase member that are each configured to engage the second nerve 
application under 35 U . S . C . § 371 of International Appli segment to inhibit the second nerve segment from moving 
cation No . PCT / US12 / 26764 , filed Feb . 27 , 2012 , which away from the first nerve segment in a longitudinal direc 
claims the benefit of U . S . Provisional Patent Application No . 10 tion . The first coupling member and the second coupling 
61 / 446 , 803 , filed Feb . 25 , 2011 , the disclosures of which are member are movable relative to each other in a transverse 
hereby incorporated by reference in their entirety . direction substantially perpendicular to the longitudinal 
direction to inhibit nerve compression . STATEMENT OF FEDERALLY SPONSORED 
RESEARCH OR DEVELOPMENT In another aspect , the present invention provides an apparatus for coaptation of a first nerve segment separated 
Not applicable . from a second nerve segment . The apparatus includes a first coaptation member configured to extend about the first nerve 
BACKGROUND OF THE DISCLOSURE segment , and the first coaptation member includes a first 
20 coupling member configured to engage the first nerve seg 
The present disclosure generally relates to a nerve coap ment . The apparatus further includes a second coaptation 
tation apparatus and , more particularly , to a microsuture - less member configured to extend about the second nerve seg 
nerve coaptation apparatus having relatively - movable cou - ment , and the second coaptation member includes a second 
pling members to inhibit nerve compression in the event of , coupling member configured to engage the second nerve 
for example , nerve swelling . | 25 segment . The second coupling member connects to the first 
Microsurgery ( that is , surgery aided by use of a micro - coupling member to inhibit the first and second coaptation 
scope ) is used in various types of medical procedures that members from moving apart in a longitudinal direction and 
treat relatively small bodily structures , such as coaptation of to inhibit the first and second nerve segments from moving 
severed nerves . In this case , the procedure typically involves apart in the longitudinal direction . The first coupling mem 
using a relatively small suture to connect the severed ends of 30 ber and the second ber and the second coupling member are movable in a the severed nerve segments . This facilitates axonal growth to transverse direction substantially perpendicular to the lon fuse the nerve segments , which ideally restores some degree gitudinal direction to inhibit nerve compression . of nerve functionality . In yet another aspect , the present invention provides an Unfortunately , nerve coaptation microsutures have sev 
eral limitations . For example , connecting severed nerve 35 35 apparatus for coaptation of a first nerve segment separated from a second nerve segment . The apparatus includes a first segments with a microsuture is a relatively long procedure 
that requires considerable surgical experience . Furthermore , coupling pair having a first coupling member configured to 
the outcome of such procedures are typically considered connect to the first nerve segment and a second coupling 
poor due to relatively long recovery times ( for example , up member configured to connected to the second nerve seg 
to several years ) and limited nerve functionality ( for 40 ment . The first coupling member connects to the second 
example , less than 20 percent of original nerve functional coupling member to engage the first nerve segment with the 
ity ) . second nerve segment . The apparatus further includes a 
Nerve coaptation couplings have been proposed for use in second coupling pair having a third coupling member con 
addition to microsutures in an attempt to address the above figured to connect to the first nerve segment and a fourth 
limitations . Such couplings typically include a sleeve that 45 coupling member configured to connected to the second 
houses and isolates the ends of the severed nerve segments , nerve segment . The third coupling member connects to the 
and pharmaceutical agents can be incorporated into the fourth coupling member to engage the first nerve segment 
sleeve to promote axonal growth . Unfortunately , such with the second nerve segment . The first coupling pair is 
devices inhibit nerve swelling proximate the ends of the movable relative to the second coupling pair to inhibit 
severed nerve segments , which inwardly compresses the 50 compression of the first nerve segment and the second nerve 
nerve segments and can adversely affect nerve regeneration . segment . 
Considering the above , what is needed is a nerve coap - The foregoing and other objects and advantages of the 
tation apparatus that addresses one or more of the short invention will appear in the detailed description that follows . 
comings of microsutures and previous coaptation devices . In the description , reference is made to the accompanying 
55 drawings that illustrate a preferred configuration of the 
SUMMARY OF THE INVENTION invention . 
BRIEF DESCRIPTION OF THE DRAWINGS The present invention generally provides an apparatus for 
coaptation of first and second severed nerve segments . The 
apparatus includes a plurality of nerve - engaging features or 60 
“ coupling members ” that each connect to another coupling 
member to form " coupling pairs ” . The coupling pairs are 
advantageously movable relative to each other to permit 
nerve swelling and inhibit nerve compression . 
In one aspect , the present invention provides an apparatus 65 
for coaptation of a first nerve segment separated from a 
second nerve segment . The apparatus includes a first coap - 
The present invention will hereafter be described with 
reference to the accompanying drawings , wherein like ref 
erence numerals denote like elements , and : 
FIG . 1 is a side schematic view of a nerve coaptation 
apparatus according to the present invention ; 
FIG . 2 is a side perspective view of a first configuration 
of the nerve coaptation apparatus of FIG . 1 before connect 
ing two coaptation members ; 
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FIG . 3 is a side view of the first configuration of the nerve The first coaptation member 102 includes a plurality of 
coaptation apparatus of FIG . 2 upon connecting the two coupling members 106 , which may comprise various mate 
coaptation members ; rials commonly associated with medical devices , such as 
FIG . 4 is an end view of one of the coaptation members implantable , biodegradable , and non - neurotoxic polymers 
of FIG . 2 ; 5 and the like . Each of the coupling members 106 includes a 
FIG . 5 is a detail view of the area of one of the coaptation semi - cylindrical wall 108 , and together the walls 108 pro 
members enclosed by line 5 - 5 of FIG . 2 ; vide the first coaptation member 102 with a cylindrical 
FIG . 6 is a side perspective view of a second configuration shape for receiving the first nerve segment 10 . That is , the 
of the nerve coaptation apparatus of FIG . 1 before connect coupling members 106 together define open ends 110 , 112 
ing two coaptation members ; 10 through which the nerve segment 10 extends and an internal 
FIG . 7 is a side perspective view of the second configu nerve passageway 114 that receives nerve segment 10 . 
ration of the nerve coaptation apparatus of FIG . 6 upon Furthermore , the coupling members 106 together define a 
connecting the two coaptation members ; longitudinal direction of the coaptation member 102 extend 
FIG . 8 is an end view of one of the coaptation members ing between the open ends 110 , 112 and aligned with the 
of FIG . 6 ; 15 longitudinal direction of the nerve segment 10 . 
FIG . 9 is a perspective view of two coupling members of To permit the coupling members 106 to move relative to 
the second configuration of the nerve coaptation apparatus each other , the first coaptation member 102 includes a 
of FIG . 6 ; plurality of expandable or flexible joints 116 connecting the 
FIG . 10 is a side perspective view of a third configuration sides of adjacent coupling members 106 . The flexible joints 
of the nerve coaptation apparatus of FIG . 1 before connect - 20 116 may comprise various materials , such as elastically 
ing two coaptation members ; deformable , implantable , biodegradable , and non - neuro 
FIG . 11 is a side perspective view of the third configu - toxic polymers and the like . In any case , the flexible joints 
ration of the nerve coaptation apparatus of FIG . 10 upon 116 permit the coupling members 106 to move in a trans 
connecting the two coaptation members ; verse direction ( that is , a direction perpendicular to the 
FIG . 12 is a side perspective view of separation of two 25 longitudinal direction within five degrees ) relative to one 
halves of one of the coaptation members of FIG . 10 ; another . Such relative motion between the coupling mem 
FIG . 13 is a flow chart setting forth steps of a pharma - bers 106 advantageously permits nerve swelling ( by up to , 
ceutical agent delivery sequence conducted by the apparatus for example , 50 percent ) and inhibits nerve compression . 
of FIG . 1 ; The first coaptation member 102 includes several features 
FIG . 14A is a plot of sciatic function index scores versus 30 to engage the first nerve segment 10 and the second coap 
post - operative time for various types of nerve injuries and tation member 104 proximate the open end 110 . To connect 
pharmaceutical agent sequences ; and to the nerve segment 10 , each of the coupling members 106 
FIG . 14B is a plot of foot fault asymmetry scores versus includes a hooked epineurium pin 118 . As the name implies , 
post - operative time for various types of nerve injuries and each epineurium pin 118 pierces the epineurium of the nerve 
pharmaceutical agent sequences . 35 segment 10 . As such , the epineurium pins 118 inhibit the 
nerve segment 10 from moving longitudinally relative to the 
DETAILED DESCRIPTION OF THE coaptation member 102 . In addition , the epineurium pins 
INVENTION 118 hold the nerve segment 10 in an appropriate position for 
coaptation with the second nerve segment 12 ( that is , 
Referring now to FIG . 1 , the present invention provides 40 proximate the open end 110 ) when the coaptation members 
an apparatus 50 for coaptation of first and second severed 102 , 104 are connected . 
nerve segments 10 , 12 . Generally , the apparatus 50 includes To connect the first coaptation member 102 to the second 
a first coaptation member 52 that surrounds and engages the coaptation member 104 , each of the coupling members 106 
first nerve segment 10 and a second coaptation member 54 includes two longitudinally extending connection elements 
that surrounds and engages the second nerve segment 12 . 45 120 , 122 proximate the first open end 110 . Half of the 
The first and second coaptation members 52 , 54 abut each connection elements are tapering posts 120 and half of the 
other to coapt the ends of the first and second nerve connection elements are holes 122 . Each hole 122 receives 
segments 10 , 12 . In addition , the first and second coaptation one of the tapering posts 120 on the second coaptation 
members 52 , 54 include nerve - engaging features or " cou - member 104 , and each tapering post 120 is received in one 
pling members ” that each connect to a coupling member on 50 of the holes 122 on the second coaptation member 104 . In 
the opposite coaptation member 52 , 54 to form " coupling addition , each tapering post 120 may be press - fittingly 
pairs ” . The coupling pairs are advantageously movable received in the corresponding hole 122 to provide a firm 
relative to each other to permit nerve swelling and inhibit connection between the coaptation members 102 , 104 . Such 
nerve compression . Various configurations of the apparatus a connection may inhibit the coaptation members 102 , 104 
50 and the coupling members are described below . 55 from moving apart in the longitudinal direction once con 
The coaptation members 52 , 54 also receive one or more nected . 
pharmaceutical agents from an agent delivery device 56 to One or more of the coupling members 106 also include 
facilitate repair and fusion of the nerve segments 10 , 12 . features to ensure proper angular alignment of the nerve 
Various pharmaceutical agents may be used , although segments 10 , 12 ( that is , proper alignment of individual 
advantageous pharmaceutical agents are described below . 60 axons and the like ) . Specifically , on each of the coaptation 
Regardless of the specific type used , the pharmaceutical members 102 , 104 , one of the coupling members 106 
agents are subsequently evacuated to a collection device 58 . includes a plurality of strips 124 , 126 , and 128 of different 
Turning now to FIGS . 2 - 5 , a first configuration of the colors . When connecting the nerve segments 10 , 12 to the 
nerve coaptation apparatus 100 is shown . In this configura coaptation members 102 , 104 , respectively , common fea 
tion , the first and second coaptation members 102 , 104 are 65 tures of the nerve segments 10 , 12 ( for example , fascicle 
generally similar , and therefore only the first coaptation patterns or the like ) may be aligned with a specific strip 124 , 
member 102 is described in detail herein . 126 , or 128 . Then , when connecting the coaptation members 
US 10 , 136 , 894 B2 
102 , 104 to each other , matching color strips 124 , 126 , and The first coaptation member 202 also includes inlet and 
128 on the coaptation members 102 , 104 are aligned to outlet passageways 218 , 220 to receive and evacuate one or 
ensure that the features of the nerve segments 10 , 12 are more pharmaceutical agents , respectively . In this configu 
aligned . Furthermore , the coupling members 106 could be ration , the inlet and outlet passageways 218 , 220 are defined 
translucent or transparent to permit the nerve segments 10 , 5 adjacent to bridges 222 that connect opposite semi - cylindri 
12 to be viewed therethrough . cal halves 224 of the coaptation member 202 . 
During deployment , the coaptation members 102 , 104 As described briefly above , the first coaptation member 
may be moved towards each other and joined using a linear 202 releasably supports a plurality of coupling members 226 , 228 on the inner surface of the wall 206 . The coupling or hinged coupling applicator , such as those used for vas 10 members 226 , 228 engage and hold the first nerve segment cular anastomoses . Other deployment devices may alterna 10 in contact with the second nerve segment 12 . As such , the tively be used . coupling members 226 , 228 may comprise various materials After deployment , one or more pharmaceutical agents commonly associated with medical devices , such as may be delivered from the agent delivery device , through an implantable , biodegradable , and non - neurotoxic polymers 
inlet passageway 130 defined by one of the coupling mem - 15 and the like . 
bers 106 , and into the nerve passageways 114 to facilitate To engage and hold the first nerve segment 10 in contact 
repair and fusion of the nerve segments 10 , 12 . After a with the second nerve segment 12 , half of the coupling 
specified amount of time , the pharmaceutical agents are members 226 have tapering shapes and act as epineurium 
evacuated through an outlet passageway 132 defined by one pins that pierce the epineurium of the nerve segment 10 . In 
of the coupling members 106 and into the collection device . 20 addition , these coupling members 226 are fixedly received 
The first configuration of the nerve coaptation apparatus by a corresponding pin - receiving coupling member 228 of 
100 may be modified in other manners that are not explicitly the second coaptation member 204 . Similarly , each pin 
described above . For example , the coupling members 106 receiving coupling member 228 of the first coaptation mem 
may include more or less than two connection elements 120 , ber 202 fixedly receives one of the epineurium pin coupling 
122 and one epineurium pin 118 ( for example , each coap - 25 members 226 of the second coaptation member 204 . 
tation member 102 and 104 may include twelve connection After receiving the nerve segments 10 , 12 , connecting to 
elements 120 , 122 and six epineurium pins 118 ) . As another each other , and delivering and evacuating the pharmaceuti 
example , the inlet passageway 130 and outlet passageway cal agents , the coaptation members 202 , 204 detach from the 
132 may be omitted , and gaps defined by the flexible joints coupling members 226 , 228 , for example , by breaking the 
116 and the sides of adjacent coupling members 106 may 30 bridges 222 and an adhesive connection between the coap 
serve as inlet and outlet passageways . tation members 202 , 204 and the coupling members 226 , 
Turning now to FIGS . 6 - 9 , a second configuration of the 228 . The coupling members 226 , 228 remain connected to 
nerve coaptation apparatus 200 is shown . In this configura - each other and the nerve segments 10 , 12 . As such , the 
tion , the apparatus 200 includes a first coaptation member coupling members 226 , 228 inhibit the nerve segments 10 , 
and a second coaptation member 202 , 204 that are generally 35 12 from moving apart in the longitudinal direction . How 
similar . As such , only the first coaptation member 202 is ever , each pair of coupling members 226 , 228 is movable in 
described in detail herein . In general , the first coaptation the transverse direction relative to the other pairs . The 
member 202 permits nerve swelling and inhibits compres - coupling members 226 , 228 thereby permit nerve swelling 
sion by deploying a plurality of relatively movable coupling and inhibit compression . 
members . This aspect is described in further detail below . 40 Turning now to FIGS . 10 - 12 , a third configuration of the 
The first coaptation member 202 may comprise various nerve coaptation apparatus 300 is shown . The third configu 
materials commonly associated with medical devices , such ration of the apparatus 300 shares many features with the 
as non - neurotoxic polymers and the like . The first coaptation second configuration of the nerve coaptation apparatus 200 . 
member 202 includes a wall 206 that defines a cylindrical For example , the coaptation members 302 , 304 may com 
shape for receiving the first nerve segment 10 . That is , the 45 prise various materials commonly associated with medical 
wall 206 defines open ends 208 , 210 through which the devices , such as non - neurotoxic polymers and the like . 
nerve segment 10 extends and an internal nerve passageway Furthermore , each coaptation member 302 , 304 includes a 
212 that receives nerve segment 10 . Furthermore , the coap - plurality of connection elements 306 , 308 like those 
tation member 202 defines a longitudinal direction extend described above and a plurality of detachably supported and 
ing between the open ends 208 , 210 and aligned with the 50 nerve - engaging coupling members 310 , 312 like those 
longitudinal direction of the nerve segment 10 . described above . Each coaptation member 302 , 304 also 
The first coaptation member 202 also supports connection includes inlet and outlet passageways 314 , 316 to receive 
elements 214 , 216 , such as those described above , to connect and evacuate one or more pharmaceutical agents , respec 
to the second coaptation member 204 . That is , the coaptation tively . 
member 202 includes a plurality of longitudinally extending 55 In contrast to the second configuration , each coaptation 
connection elements 214 , 216 proximate the first open end member 302 , 304 includes two separate semi - cylindrical 
208 . Half of the connection elements are tapering posts 214 halves 318 that are initially held in abutment by a semi 
and half of the connection elements are holes 216 . Each hole cylindrical deployment element 320 . As such , after connect 
216 receives one of the tapering posts 214 on the second ing the nerve segments 10 , 12 to the coupling members 310 , 
coaptation member 204 , and each tapering post 214 is 60 312 and connecting the coaptation members 302 , 304 to 
received in one of the holes 216 on the second coaptation each other , the deployment elements 320 are detached from 
member 204 . In addition , each tapering post 214 may be the coaptation members 302 , 304 by , for example , moving 
press - fittingly received in the corresponding hole 216 to the deployment elements 320 apart in the longitudinal 
provide a firm connection between the coaptation members direction . Thereafter , and as shown in FIG . 12 , the coapta 
202 , 204 . Such a connection may inhibit the coaptation 65 tion member halves 318 are separated from each other , the 
members 202 , 204 from moving apart in the longitudinal coupling members 310 , 312 , and the nerve segments 10 , 12 
direction once connected . by moving apart in the transverse direction . 
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For each of the above configurations , the coaptation include a sequence of : 1 ) a hypotonic calcium - free solution 
members may provide a range of sizes appropriate for use ( for example , a solution as shown below in Tables 1 and 2 
with digital nerve repair ( about 1 mm in diameter ) up to applied for a period of about 60 seconds before evacuation ) ; brachial root repair ( about 1 cm in diameter ) . 
Turning now to FIGS . 13 , 14A , and 14B and as briefly 5 2 ) 2 ) antioxidants / inhibitors of membrane sealing ( for 
described above , the coaptation members may receive one or example , 2 mM melatonin or 100 UM USP methylene blue 
more pharmaceutical agents from the agent delivery device applied for a period of about 90 seconds before evacuation ) ; 
to facilitate repair and fusion of the nerve segments . The 3 ) a lipid membrane fusogen ( for example , 5 g polyethylene 
agent delivery device may be one or more syringes ( in the glycol 2000 ( PEG ) dissolved in 5 mL distilled water applied 
case of a single syringe , multiple agents may be separately 10 for about 90 seconds before evacuation ) ; and ; 4 ) isotonic 
compartmentalized ) , a manifold that automatically delivers 
pharmaceutical agents , or the like . calcium - containing solution ( for example , a solution as 
Regardless of the specific type of agent delivery device , shown below in Tables 3 - 5 applied for a period of about 
the pharmaceutical agents preferably and advantageously 120 - 180 seconds before evacuation ) . 
TABLE 1 
Hypotonic calcium - free solution . Chemicals dissolved in 1000 mL distilled 
water , buffering pH with HCl or NaOH , respectively , added drop - wise . 




58 . 44 
74 . 56 







10 . 0 
2 . 4 1 1 2 




Sodium Chloride 5 . 7856 g 
Potassium Chloride 0 . 3728 g 
Potassium 0 . 1634 g 
Phosphate 
Magnesium Sulfate 0 . 1566 g 
Sodium Bicarbonate 2 . 1842 g 
Sodium Ascorbate 1 . 981 g 
Dextrose 
Solution A ( see 50 mL 
Table 2 ) 
120 . 39 
84 . 01 
198 . 1 
180 . 16 





9 . 9 
8 . 55 WANNN 
2 . 6 
50 . 0 
20 . 0 
10 . 0 
25 . 7 
1 . 8 g 
85 . 49 / 10 
273 . 7 
318 . 7 
TABLE 2 
Solution A . Dissolved in 500 mL distilled water . 
Symbol Chemical 
MgCl Magnesium 
Amount ( g ) MW Multiplicand mM / L 
4 . 07 95 . 21 2 85 . 49 
Species mOsm / L 
3 256 . 47 
Chloride 
TABLE 3 
Isotonic calcium - containing solution . Buffer pH with HCl or NaOH , 
respectively , added drop - wise . Mix cold . 
Symbol Chemical Amount 
475 mL 
MW 
473 . 49 
mM / L Species mOsm / L 
331 . 55 1 314 . 97 
H2O 475 mL 18 
Solution B 
( see Table 4 ) 
Distilled Water 
Solution C 




NaC6H , 06 
50 mL 
1 . 981 g 
1 . 8 g 
111 . 0 
198 . 1 
180 . 16 
10 




6 . 0 
20 
9 . 9 C6H1206 
350 . 87 
TABLE 4 
Solution B . Chemicals dissolved in 4000 mL distilled water . 





61 . 024 
3 . 139 
58 . 44 
74 . 56 
4 
4 
261 . 05 
10 . 5 
2 
2 
522 . 1 
21 KCI 
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TABLE 4 - continued 
Solution B . Chemicals dissolved in 4000 mL distilled water . 
Amount ( g ) 
1 . 374 
MW Divisor mM / L 
136 . 094 2 . 52 
Species mOsm / L 







1 . 318 120 . 39 2 . 74 5 . 48 
18 . 394 18 . 394 84 . 01 84 . 01 4 54 . 74 54 . 74 2 109 . 48 109 . 48 
Bicarbonate 
473 . 49 331 . 55 663 . 1 
TABLE 5 15 In some configurations , the at least one of the antioxidant 
and the inhibitor of membrane sealing includes one of USP 
Solution C . Dissolved in 1000 mL distilled water . methylene blue and melatonin . 
Symbol Chemical Amount ( g ) MW mM / L Species mOsm / L In some configurations , the at least one lipid membrane 
fusogen includes polyethylene glycol .
CaCl2 Calcium 4 . 44 111 . 0 40 3 120 20 In some configurations , the method further comprises the Chloride steps of : 
delivering at least one hypotonic calcium - free solution to 
Alternatively , the hypotonic calcium - free solution may be the nerve ; and 
additionally applied to the nerve after the antioxidants / evacuating the at least one hypotonic calcium - free solu 
inhibitors of membrane sealing and before the lipid mem - 25 tion away from the nerve before delivering the at least 
brane fusogen to wash away USP methylene blue stains on one of the antioxidant and the inhibitor of membrane 
the nerve segments . sealing . 
Data collected by the present inventors and partially In some configurations , the method further comprises the 
illustrated in FIGS . 14A and 14B indicates that antioxidants / 
inhibitors of membrane sealing , such as USP methylene blue 30 delivering at least one isotonic calcium - containing solu 
and melatonin , maintain the axonal ends of severed nerve tion to the nerve after evacuating the at least one lipid 
segments in an open and vesicle - free state appropriate for membrane fusogen ; and 
repair by a lipid membrane fusogen , such as PEG . Further evacuating the at least one isotonic calcium - containing 
more , these data also indicate that the above sequence solution away from the nerve . 35 In some configurations , the nerve includes a first segment advantageously improves recovery time and nerve function severed from and abutting a second segment , and each of the compared to microsutures , specifically by a factor of up to at least one of the antioxidant and the inhibitor of membrane two and 40 percent in four months , respectively . sealing and the at least one lipid membrane fusogen are 
After the specified contact period with the nerve seg delivered to and evacuated away from the first segment and 
ments , each pharmaceutical agent may be evacuated by 40 the second segment . 
applying vacuum pressure , permitting free drainage , capil - The pharmaceutical agents may be provided in a kit . Such 
lary action ( for example , by connecting the outlet passage - a kit may be summarized as follows . 
way to an absorbent surgical material ) , or the like . Further - A kit for use in a pharmaceutical agent delivery sequence , 
more , the actions of the delivery device and the collection comprising : 
device can be coordinated , for example , via an electronic 45 at least one of an antioxidant and an inhibitor of mem 
controller ( not shown ) and a plurality of valves ( not shown ) , brane sealing ; 
such that each pharmaceutical agent contacts the nerve at least one lipid membrane fusogen ; and 
segments for the specified contact period . Such a controller instructions indicating that the pharmaceutical agent deliv 
may also control the delivery pressure of the pharmaceutical ery sequence includes at least one of the antioxidant and the 
agents . That is , the controller may provide the agents at a 50 inhibitor of membrane sealing followed by the at least one 
pressure sufficiently low to maintain contact of the ends of lipid membrane fusogen . 
the nerve segments , and sufficiently high to ensure adequate From the above description , it should be apparent that the 
distribution of the chemicals over the nerve segments . present invention provides a nerve coaptation apparatus that 
The pharmaceutical agent delivery sequence may be includes a plurality of nerve - engaging coupling pairs . The 55 coupling pairs are advantageously movable relative to each summarized as follows . other to permit nerve swelling and inhibit nerve compres A method for treatment of a nerve , comprising the steps sion . 
The various configurations presented above are merely 
delivering at least one of an antioxidant and an inhibitor examples and are in no way meant to limit the scope of this 
of membrane sealing to the nerve ; 60 disclosure . Variations of the configurations described herein 
evacuating the at least one of the antioxidant and the will be apparent to persons of ordinary skill in the art , such 
inhibitor of membrane sealing away from the nerve ; variations being within the intended scope of the present 
delivering at least one lipid membrane fusogen to the application . In particular , features from one or more of the 
nerve after evacuating the at least one of the antioxidant above - described configurations may be selected to create 
and the inhibitor of membrane sealing ; and 65 alternative configurations comprised of a sub - combination 
evacuating the at least one lipid membrane fusogen away of features that may not be explicitly described above . In 
from the nerve . addition , features from one or more of the above - described 
of : 
12 
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configurations may be selected and combined to create 14 . The method of claim 1 , wherein the antioxidant is 
alternative configurations comprised of a combination of melatonin . 
features which may not be explicitly described above . Fea - 15 . A method of coaptation of a first and second nerve 
tures suitable for such combinations and sub - combinations segments having cut but not crushed ends , said segments 
would be readily apparent to persons skilled in the art upon 5 being segments of a nerve that has been cut but not crushed 
review of the present application as a whole . The subject comprising the steps of : 
matter described herein and in the recited claims intends to a ) applying a hypotonic , calcium - free saline solution to cover and embrace all suitable changes in technology . said first and second cut nerve segments of a nerve that 
What is claimed is : has been cut but not crushed , for a first period of time ; 1 . A method of coaptation of a first and second nerve 10 b ) bringing into contact the cut end of the first nerve segments having cut but not crushed ends , said segments 
being segments of a nerve that has been cut but not crushed segment with the cut end of the second nerve segments ; 
comprising the steps of : c ) after step a ) , applying to said nerve segments a solution 
a ) applying a hypotonic , calcium - free saline solution to containing an antioxidant inhibitor of membrane seal 
said first and second cut but not crushed nerve seg - 15 ing and a lipid membrane fusogen for a second period 
ments of a nerve that has been cut but not crushed , for of time ; 
a first period of time ; d ) applying to the contacted nerve segments an isotonic , 
b ) concurrent with or after step a ) , applying to said nerve calcium - containing solution for a fourth period of time , 
segments a solution containing an antioxidant inhibitor to thereby coapt said contacted nerve first and second nerve segments . of membrane sealing for a second period of time ; 20 
c ) bringing into contact a cut end of the first nerve 16 . A method of coaptation of a first and second nerve segments , said segments being segments of a nerve , the segment with a cut end of the second nerve segments ; 
d ) then applying a lipid membrane fusogen solution to method comprising the steps of : 
said contacted first and second nerve segments for a a ) applying a hypotonic , calcium - free saline solution to 
third period of time ; and 25 said first and second nerve segments for a first period 
( e ) applying to the contacted nerve segments an isotonic , of time ; 
calcium - containing solution for a fourth period of time , b ) concurrent with or after step a ) , applying to said nerve 
to thereby coapt said contacted nerve first and second segments a solution containing an antioxidant inhibitor 
nerve segments . of membrane sealing for a second period of time ; 
2 . The method of claim 1 , wherein said first and second 30 C ) bringing into contact ends of the first and second 
nerve segments having cut but not crushed ends are in a segments ; 
human patient . d ) then applying a lipid membrane fusogen solution to 
3 . The method of claim 1 , wherein the hypotonic , cal said contacted first and second nerve segments for a 
cium - free solution comprises sodium chloride , potassium third period of time ; and 
chloride , potassium phosphate , magnesium sulfate , sodium 35 ( e ) applying to the contacted nerve segments an isotonic , ( e ) applyin 
bicarbonate , sodium ascorbate , and / or dextrose . calcium - containing solution for a fourth period of time , 
4 . The method of claim 1 , wherein said lipid membrane to thereby coapt said contacted first and second nerve 
fusogen comprises polyethylene glycol ( PEG ) . segments . 
5 . The method of claim 4 , wherein the PEG is present at 17 . The method of claim 16 , wherein the antioxidant is 
a concentration of from 100 to 500 mM . 40 methylene blue . 
6 . The method of claim 1 , wherein following the first * 18 . The method of claim 16 , wherein the antioxidant is 
second , third and fourth periods of time , the respective melatonin . 
solution is evacuated . 19 . The method of claim 16 , wherein the hypotonic , 
7 . The method of claim 1 , wherein the first period of time calcium - free solution comprises sodium chloride , potassium 
is about 60 seconds , the second period of time is about 90 45 chloride , potassium phosphate , magnesium sulfate , sodium 
seconds , the third period of time is about 90 seconds and the bicarbonate , sodium ascorbate , and / or dextrose . 
fourth period of time is about 120 to 180 seconds . 20 . The method of claim 19 , further comprising a further 
8 . The method of claim 1 , wherein the lipid membrane application of a hypotonic calcium - free solution to the nerve 
fusogen is applied for about 90 seconds before evacuation . after step b ) and / or after step c ) . 
9 . The method of claim 1 . wherein the isotonic , calcium - 50 21 . The method of claim 16 , wherein said lipid membrane 
containing solution is applied for about 120 - 180 seconds fusogen comprises polyethylene glycol ( PEG ) . 
22 . The method of claim 21 , wherein the PEG is present before evacuation . 
10 . The method of claim 1 , further comprising a further at a concentration of from 100 to 500 mM . a 
application of a hypotonic calcium - free solution to the nerve 23 . The method of claim 16 , wherein following the first , 
after step b ) and / or after step c ) . se second , third and fourth periods of time , the respective 
11 . The method of claim 1 , wherein the solutions are solution is evacuated . 24 . The method of claim 23 , wherein the first period of contained within syringes . 
12 . The method of claim 1 . wherein the hypotonic . time is about 60 seconds , the second period of time is about 
calcium - free saline and the solution containing an antioxi 90 seconds , the third period of time is about 90 seconds and 
dant are comprised in separate barrels of a double - barreled 60 ed so the fourth period of time is about 120 to 180 seconds . 
syringe . 25 . The method of claim 16 , wherein said first and second 
13 . The method of claim 1 , wherein the antioxidant is dontic nerve segments are in a human patient . ne 
methylene blue . * * * * * 
